Factor VIIa in Hemophilia Surgery: Phase 3 Results Posted After Early Termination

원문 링크: WordPress 원문

LFB, the French biopharmaceutical company, posted Phase 3 trial results on ClinicalTrials.gov on July 31, 2026, evaluating recombinant Factor VIIa for surgical bleeding prevention in hemophilia patients with inhibitors undergoing major surgery, reporting one excellent or good hemostatic rating among the two participants who completed the protocol. The extremely small sample size and early termination for feasibility leave the efficacy and safety profile entirely unresolved, though the absence of deaths or serious adverse events in this minimal cohort offers a preliminary safety signal for this rare-disease population.

The results table for this terminated Phase 3 study was first posted to ClinicalTrials.gov on July 31, 2026, making these data publicly available for the first time.

2 enrolled

participants before termination

1 of 2

excellent or good hemostasis

0 deaths

and 0 serious adverse events

English한국어

AI-generated conceptual illustration; not study data.

Two Procedures, One Protocol-Defined Hemostatic Success

Design: Phase 3, single-group, open-label, terminated Enrolled: 2 males aged 12–65 with hemophilia A or B and inhibitors (BU ≥ 5) Analysis population: 2 participants (same as enrolled; no separate analysis population defined) Primary endpoint: Hemostatic effectiveness by protocol aggregate score (excellent/good vs moderate/poor)

The trial enrolled two male participants aged 12 to 65 with congenital hemophilia A or B and high-titer inhibitors (Bethesda units of 5 or greater) who were scheduled for elective major surgery. The intervention was eptacog beta (activated), a recombinant Factor VIIa product, administered as a 200 microgram per kilogram intravenous bolus at the start of surgery followed by 75 microgram per kilogram bolus doses every two hours for at least 72 hours after wound closure, with a minimum treatment duration of five days. The primary endpoint was hemostatic effectiveness assessed by a protocol-defined aggregate score that classified each surgical procedure as excellent or good versus moderate or poor based on intraoperative blood loss, transfusion requirements, and postoperative drainage volumes. Among the two completed procedures, one received an excellent or good rating and one received a moderate or poor rating under the protocol aggregate scoring system. A post-hoc review by the independent data monitoring committee classified both procedures as excellent or good, a discrepancy that highlights the sensitivity of the aggregate scoring methodology in very small samples. No deaths occurred during the study period, and no serious adverse events were reported. Two other adverse events were recorded among the two participants, consistent with the expected surgical and disease-related morbidity in this population. The sponsor terminated the trial citing feasibility considerations, specifically extended timelines to complete recruitment in this extremely rare patient population.

AI-generated conceptual illustration; not study data.

Surgical Bleeding in Inhibitor Patients Remains a Critical Unmet Need

Hemophilia patients who develop inhibitors against standard clotting factor replacement therapy represent one of the most challenging populations in surgical medicine. Without effective hemostatic agents, even routine surgical procedures carry life-threatening bleeding risk. Recombinant activated Factor VIIa products bypass the inhibited clotting pathway and have been used as rescue agents for decades, but prospective Phase 3 evidence in the elective major surgery setting remains scarce. The posting of these results, even from a two-patient cohort, adds a data point to the evidence base for eptacog beta (activated) in this specific clinical context. The absence of deaths and serious adverse events, while uninformative at this sample size, is consistent with the known safety profile of recombinant Factor VIIa products in hemophilia. For clinicians managing surgical planning in inhibitor patients, registry data and case series remain the primary evidence source, and this early termination underscores the structural difficulty of generating prospective randomized evidence in ultra-rare conditions. The discrepancy between the protocol aggregate score and the data monitoring committee post-hoc assessment also raises methodological questions about how hemostatic effectiveness should be measured and adjudicated in small surgical trials, where individual patient variability can dominate composite scoring systems.

Sample Size and Open-Label Design Preclude Efficacy Conclusions

The most fundamental limitation is the sample size. With only two enrolled participants, no statistical inference about efficacy or safety is possible. The trial was designed as a Phase 3 confirmatory study but never approached its target enrollment, and the sponsor stated feasibility as the reason for termination, specifically the extended timelines required to identify and recruit eligible patients in this ultra-rare population. The single-group, open-label design without a comparator arm means that even the descriptive results cannot be attributed to the intervention with confidence. The protocol aggregate hemostatic score, which produced a split result of one excellent or good and one moderate or poor, was overridden by a post-hoc data monitoring committee review that rated both procedures as excellent or good, introducing uncertainty about which assessment is more clinically meaningful. Safety reporting in a two-patient cohort is inherently limited: zero deaths and zero serious adverse events are reassuring but cannot exclude rare or delayed toxicity. The two recorded other adverse events were not further characterized in the posted results table. The study population was restricted to males aged 12 to 65, excluding pediatric patients under 12, older adults, and females, which limits generalizability. The intervention dosing regimen, while consistent with published recombinant Factor VIIa protocols, was not compared against alternative bypassing agents such as activated prothrombin complex concentrate.

AI-generated conceptual illustration; not study data.

Feasibility Barriers Shape the Future Evidence Landscape

The feasibility-driven termination of this trial raises broader questions about the conduct of prospective interventional studies in ultra-rare hemophilia subpopulations. The sponsor, LFB, has not announced plans for a replacement trial or an amended protocol with relaxed eligibility criteria. For the clinical community, the posted results serve primarily as a transparency record rather than as actionable evidence. Regulatory agencies including the European Medicines Agency and the U.S. Food and Drug Administration have not evaluated eptacog beta (activated) for this specific surgical indication based on these data, and the existing authorization status of the product remains unchanged. Future evidence generation in this population is more likely to come from international registries, compassionate use programs, and pooled case series than from additional randomized trials. Clinicians managing surgical hemostasis in inhibitor patients should continue to rely on established guidelines, institutional experience, and the broader published literature on bypassing agents. The posting of these results on ClinicalTrials.gov fulfills a regulatory transparency obligation and provides the research community with a complete, if minimal, dataset for future meta-analytic or systematic review purposes. Patients and caregivers should discuss surgical bleeding management options with their treating hematologist rather than drawing conclusions from a two-participant terminated trial.

These results are from a terminated Phase 3 trial registered on ClinicalTrials.gov and do not constitute peer-reviewed published evidence. The extremely small sample size of two participants precludes any efficacy or safety conclusion. Registration results are not equivalent to regulatory approval or clinical guideline endorsement. Association between the intervention and observed outcomes cannot be established from this uncontrolled, terminated study.

ClinicalTrials.gov NCT05695391 — Full Study Record

This article is for informational purposes only and is not medical advice. Consult a qualified healthcare professional for diagnosis and treatment decisions.